Zenas BioPharma (ZBIO) to Release Earnings on Thursday

Zenas BioPharma (NASDAQ:ZBIO) is anticipated to release its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Zenas BioPharma to post earnings of ($1.37) per share and revenue of $25.00 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 22, 2026 at 12:30 PM ET.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Monday, April 13th. The company reported ($1.10) earnings per share (EPS) for the quarter. On average, analysts expect Zenas BioPharma to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Zenas BioPharma Trading Up 3.9%

Zenas BioPharma stock opened at $20.40 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.61 and a current ratio of 5.61. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -2.61 and a beta of -0.61. Zenas BioPharma has a 1 year low of $8.53 and a 1 year high of $44.60. The firm’s 50 day moving average price is $21.74 and its two-hundred day moving average price is $26.92.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Zacks Research lowered shares of Zenas BioPharma from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 17th. Citigroup decreased their price objective on shares of Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. Guggenheim raised their price objective on shares of Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, March 16th. HC Wainwright reaffirmed a “buy” rating and issued a $44.00 price objective on shares of Zenas BioPharma in a research note on Tuesday, March 17th. Finally, Morgan Stanley raised their price objective on shares of Zenas BioPharma from $19.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 17th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $44.14.

Insider Buying and Selling at Zenas BioPharma

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. acquired 35,000 shares of Zenas BioPharma stock in a transaction that occurred on Wednesday, April 29th. The stock was acquired at an average price of $17.62 per share, with a total value of $616,700.00. Following the purchase, the chief executive officer owned 1,786,039 shares in the company, valued at approximately $31,470,007.18. This trade represents a 2.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Hongbo Lu acquired 3,768 shares of Zenas BioPharma stock in a transaction that occurred on Tuesday, March 31st. The stock was acquired at an average cost of $18.63 per share, with a total value of $70,197.84. Following the purchase, the director owned 426,736 shares in the company, valued at $7,950,091.68. The trade was a 0.89% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 259,613 shares of company stock worth $5,221,863 in the last 90 days. 22.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zenas BioPharma

Institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new stake in shares of Zenas BioPharma in the 4th quarter valued at $442,000. Alliancebernstein L.P. lifted its stake in shares of Zenas BioPharma by 12.2% in the 3rd quarter. Alliancebernstein L.P. now owns 18,350 shares of the company’s stock valued at $407,000 after purchasing an additional 1,990 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of Zenas BioPharma in the 4th quarter valued at $371,000. Bank of America Corp DE raised its holdings in Zenas BioPharma by 5.8% in the 3rd quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after acquiring an additional 818 shares during the period. Finally, Intech Investment Management LLC bought a new position in Zenas BioPharma in the 4th quarter worth $322,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.